Patent application EP19154852A (EP), filed 2019-01-31
Publication number: EP3689907A1
Title: ANTIBODIES TARGETING IL-17A AND METHODS OF USE THEREOF
Abstract: [0001]    The present invention relates to an isolated antibody which specifically binds human IL-17A, pharmaceutical compositions and methods of use thereof. The present invention further relates to a kit comprising said antibody, a nucleic acid comprising a nucleotide sequence encoding said antibody, a vector comprising said nucleic acid, a host cell comprising said nucleic acid or said vector, and a method of producing said antibody.
IPC codes: C07K  16/    24            A I
Claims: number: 1
text: An isolated antibody having a binding specificity for human IL-17A, which comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein:
number: 2
text: The antibody of claim 1, wherein said VH is VH3 or VH4, preferably VH3.
number: 3
text: The antibody of claim 1 or claim 2, wherein said VL comprises Vκ frameworks FR1, FR2 and FR3, particularly Vκ1 or VK3 FR1 to FR3, preferably Vκ1 FR1 to FR3, and a framework FR4, which is selected from a Vκ FR4, particularly Vκ1 FR4, Vκ3 FR4, and Vλ FR4, particularly Vλ FR4 comprising the amino acid sequence having at least 60, 70, 80, 90 percent identity to an amino acid sequence selected from any of SEQ ID NO: 26 to SEQ ID NO: 32, preferably Vλ FR4 as set forth in any of SEQ ID NO: 26 to SEQ ID NO: 32, preferably Vλ FR4 as set forth in SEQ ID NO: 26 or 27, more preferably Vλ FR4 as set forth in SEQ ID NO: 27.
number: 4
text: The antibody of anyone of claims 1 to 3, wherein said VH comprises an amino acid sequence that is at least 90 percent identical to the amino acid sequence SEQ ID NO: 10; and/or said VL comprises an amino acid sequence that is at least 90 percent identical to the amino acid sequence SEQ ID NO: 21.
number: 5
text: The antibody of claim 4, comprising a VH sequence of SEQ ID NO: 10 and/or a VL sequence of SEQ ID NO: 21.
number: 6
text: The antibody of any of the preceding claims, wherein said antibody:
number: 7
text: The antibody of any of the preceding claims, wherein said antibody:
number: 8
text: The antibody of any of the preceding claims, wherein said antibody:
number: 9
text: The antibody of any of the preceding claims, wherein the antibody is selected from the group consisting of: a monoclonal antibody, a chimeric antibody, a Fab, an Fv, an scFv, dsFv, an scAb, STAB, a single domain antibody (sdAb or dAb), a single domain heavy chain antibody, and a single domain light chain antibody, a VHH, a VNAR, single domain antibodies based on the VNAR structure from shark, and binding domains based on alternative scaffolds including but limited to ankyrin-based domains, fynomers, avimers, anticalins, fibronectins, and binding sites being built into constant regions of antibodies (e.g. F-star's Modular Antibody Technology™), preferably scFv.
number: 10
text: The antibody of any one of claims 1 to 9 which is a multispecific molecule.
number: 11
text: A pharmaceutical composition comprising the antibody of any one of claims 1 to 10, and a pharmaceutically acceptable carrier.
number: 12
text: The antibody of any one of claims 1 to 10, or the composition of claim 11 for use as a medicament.
number: 13
text: The antibody of any one of claims 1 to 10, or the composition of claim 11 for use in the treatment of a disorder mediated by IL-17A or a disorder that can be treated by inhibiting Gro-α secretion.
number: 14
text: A nucleic acid encoding the antibody of claims 1-10.
number: 15
text: A kit comprising the antibody of any one of claims 1 to 10, or the composition of claim 11.
Office action: search_report, dated 2020-08-05
Rejection reasons: novelty_epc_54
inventive_step_epc_56
Prior art cited: ref_id: US7807155B2
ref_type: patent
severity: background
ref_id: WO2006013107A1
ref_type: patent
severity: background
ref_id: US7838638B2
ref_type: patent
severity: background
ref_id: US8110191B2
ref_type: patent
severity: background
ref_id: WO2007070750A1
ref_type: patent
severity: background
ref_id: WO2006054059A1
ref_type: patent
severity: background
ref_id: WO2007149032A1
ref_type: patent
severity: background
ref_id: WO2008001063A1
ref_type: patent
severity: background
ref_id: WO2008021156A2
ref_type: patent
severity: background
ref_id: WO2010034443A1
ref_type: patent
severity: background
ref_id: WO2010102251A2
ref_type: patent
severity: background
ref_id: WO2012018767A2
ref_type: patent
severity: background
ref_id: WO2014161570A1
ref_type: patent
severity: background
ref_id: WO2014001368A1
ref_type: patent
severity: background
ref_id: WO2014122613A1
ref_type: patent
severity: background
ref_id: WO2015070697A1
ref_type: patent
severity: background
ref_id: WO2015137843A1
ref_type: patent
severity: background
ref_id: WO2016048188A1
ref_type: patent
severity: background
ref_id: WO2016113557A1
ref_type: patent
severity: background
ref_id: WO2016138842A1
ref_type: patent
severity: background
ref_id: WO2017068472A1
ref_type: patent
severity: background
ref_id: US7767206B2
ref_type: patent
severity: background
ref_id: US6703199B1
ref_type: patent
severity: background
ref_id: US5641870A
ref_type: patent
severity: background
ref_id: US5766886A
ref_type: patent
severity: background
ref_id: US5225539A
ref_type: patent
severity: background
ref_id: US5530101A
ref_type: patent
severity: background
ref_id: US5585089A
ref_type: patent
severity: background
ref_id: US5693762A
ref_type: patent
severity: background
ref_id: US6180370B1
ref_type: patent
severity: background
ref_id: WO2016202457A1
ref_type: patent
severity: background
ref_id: EP0404097A2
ref_type: patent
severity: background
ref_id: WO9301161A1
ref_type: patent
severity: background
ref_id: WO9957150A2
ref_type: patent
severity: background
ref_id: US5260203A
ref_type: patent
severity: background
ref_id: US5455030A
ref_type: patent
severity: background
ref_id: US4881175A
ref_type: patent
severity: background
ref_id: US5132405A
ref_type: patent
severity: background
ref_id: US5091513A
ref_type: patent
severity: background
ref_id: US5476786A
ref_type: patent
severity: background
ref_id: US5013653A
ref_type: patent
severity: background
ref_id: US5258498A
ref_type: patent
severity: background
ref_id: US5482858A
ref_type: patent
severity: background
ref_id: US4458066A
ref_type: patent
severity: background
ref_id: WO2014206561A1
ref_type: patent
severity: background
ref_id: - STARNES, T. ET AL., J IMMUNOL., vol. 167, no. 8, 2001, pages 4137 - 40
ref_type: npl
severity: background
ref_id: - AGGARWAL, S.; GURNEY, A. L., J. LEUKOC BIOL, vol. 71, no. 1, 2002, pages 1 - 8
ref_type: npl
severity: background
ref_id: - TOY D. ET AL., J IMMUNOL., 2006
ref_type: npl
severity: background
ref_id: - WRIGHT JF. ET AL., J IMMUNOL., vol. 181, no. 4, 2008, pages 2799 - 2805
ref_type: npl
severity: background
ref_id: - LIANG SC. ET AL., J IMMUNOL., vol. 179, no. 11, 2007, pages 7791 - 7799
ref_type: npl
severity: background
ref_id: - OUYANG W. ET AL., IMMUNITY, vol. 28, no. 4, 2008, pages 454 - 467
ref_type: npl
severity: background
ref_id: - MILNER JD., CURR OPIN IMMUNOL., vol. 23, no. 6, 2011, pages 784 - 788
ref_type: npl
severity: background
ref_id: - KUCHROO VK. ET AL., NAT MED., vol. 18, no. 1, 2012, pages 42 - 47
ref_type: npl
severity: background
ref_id: - AHMED M.; GAFFEN SL., CYTOKINE GROWTH FACTOR REV., vol. 21, no. 6, 2010, pages 449 - 453
ref_type: npl
severity: background
ref_id: - TRINCHIERI G., ANNU REV IMMUNOL., vol. 30, 2012, pages 677 - 706
ref_type: npl
severity: background
ref_id: - GALLIMORE AM; GODKIN A., N ENGL J MED., vol. 368, no. 3, 2013, pages 282 - 284
ref_type: npl
severity: background
ref_id: - YE P. ET AL., J EXP MED., vol. 194, no. 4, 2001, pages 519 - 527
ref_type: npl
severity: background
ref_id: - CHUNG DR. ET AL., J IMMUNOL., vol. 170, no. 4, 2003, pages 1958 - 1963
ref_type: npl
severity: background
ref_id: - HUANG W. ET AL., J INFECT DIS., vol. 190, no. 3, 2004, pages 624 - 631
ref_type: npl
severity: background
ref_id: - ISHIGAME H. ET AL., IMMUNITY, vol. 30, no. 1, 2009, pages 108 - 119
ref_type: npl
severity: background
ref_id: - GU C. ET AL., CYTOKINE, vol. 4, no. 2, 6 November 2013 (2013-11-06)
ref_type: npl
severity: background
ref_id: - CHABAUD M. ET AL., J. IMMUNOL., vol. 161, no. 1, 1998, pages 409 - 14
ref_type: npl
severity: background
ref_id: - GU ET AL., CYTOKINE, vol. 64, no. 2, November 2013 (2013-11-01)
ref_type: npl
severity: background
ref_id: - KOMIYAMA, Y. ET AL., J. IMMUNOL., vol. 177, 2006, pages 566 - 573
ref_type: npl
severity: background
ref_id: - ZIOLKOWSKA, M. ET AL., J. IMMUNOL., vol. 164, 2000, pages 2832 - 2838
ref_type: npl
severity: background
ref_id: - KOTAKE, S. ET AL., J. CLIN. INVEST., vol. 103, 1999, pages 1345 - 1352
ref_type: npl
severity: background
ref_id: - HELLINGS P.W. ET AL., AM. J. RESP. CELL MOL. BIOL., vol. 28, 2003, pages 42 - 50
ref_type: npl
severity: background
ref_id: - WANG ET AL., EUR J RHEUMATOL, 2017, pages 272 - 7
ref_type: npl
severity: background
ref_id: - MEASE PJ. ET AL., N ENGL J MED, vol. 373, 2015, pages 1329 - 39
ref_type: npl
severity: background
ref_id: - MCINNES IB. ET AL., THE LANCET, vol. 386, pages 1137 - 46
ref_type: npl
severity: background
ref_id: - MEASE PJ. ET AL., ANN RHEUM DIS., vol. 76, no. 1, January 2017 (2017-01-01), pages 79 - 87
ref_type: npl
severity: background
ref_id: - GRIFFITHS CEM ET AL., THE LANCET, vol. 386, pages 541 - 51
ref_type: npl
severity: background
ref_id: - PAPP KA. ET AL., N ENGL J MED, vol. 366, 2012, pages 1181 - 9
ref_type: npl
severity: background
ref_id: - MEASE PJ. ET AL., N ENGL J MED, vol. 370, 2014, pages 2295 - 306
ref_type: npl
severity: background
ref_id: - WANG ET AL., EUR J RHEUMATOL, vol. 4, 2017, pages 272 - 7
ref_type: npl
severity: background
ref_id: - WARD ET AL., NATURE, vol. 341, 1989, pages 544 - 546
ref_type: npl
severity: background
ref_id: - KABAT ET AL.: "Sequences of Proteins of Immunological Interest", 1991, PUBLIC HEALTH SERVICE, NATIONAL INSTITUTES OF HEALTH
ref_type: npl
severity: background
ref_id: - AL-LAZIKANI ET AL., JMB, vol. 273, 1997, pages 927 - 948
ref_type: npl
severity: background
ref_id: - LEFRANC, M.-P., THE IMMUNOLOGIST, vol. 7, 1999, pages 132 - 136
ref_type: npl
severity: background
ref_id: - LEFRANC, M.-P. ET AL., DEV. COMP. IMMUNOL., vol. 27, 2003, pages 55 - 77
ref_type: npl
severity: background
ref_id: - HONEGGER; PLUCKTHUN, J. MOL. BIOL., vol. 309, 2001, pages 657 - 670
ref_type: npl
severity: background
ref_id: - HONEGGER; PLIICKTHUN, J. MOL. BIOL., vol. 309, 2001, pages 657 - 670
ref_type: npl
severity: background
ref_id: - HOLLINGER; HUDSON, NATURE BIOTECHNOLOGY, vol. 23, no. 9, 2005, pages 1 Hel 136
ref_type: npl
severity: background
ref_id: - ZAPATA ET AL., PROTEIN ENG., vol. 8, no. 10, 1995, pages 1057 - 1062
ref_type: npl
severity: background
ref_id: - MORRISON ET AL., PROC. NATL. ACAD. SCI. U.S.A, vol. 81, 1984, pages 6851 - 6855
ref_type: npl
severity: background
ref_id: - MORRISON; OI, ADV. IMMUNOL., vol. 44, 1988, pages 65 - 92
ref_type: npl
severity: background
ref_id: - VERHOEYEN ET AL., SCIENCE, vol. 239, 1988, pages 1534 - 1536
ref_type: npl
severity: background
ref_id: - PADLAN, MOLEC. IMMUN., vol. 28, 1991, pages 489 - 498
ref_type: npl
severity: background
ref_id: - PADLAN, MOLEC. IMMUN., vol. 31, 1994, pages 169 - 217
ref_type: npl
severity: background
ref_id: - ALTSCHUL ET AL., NUCLEIC ACIDS RES., vol. 25, 1977, pages 3389 - 3402
ref_type: npl
severity: background
ref_id: - ALTSCHUL ET AL., J. MOL. BIOL., vol. 215, 1990, pages 403 - 410
ref_type: npl
severity: background
ref_id: - NEEDLEMAN; WUNSCH, J. MOL, BIOL., vol. 48, 1970, pages 444 - 453
ref_type: npl
severity: background
ref_id: - HENIKOFF, S.; HENIKOFF, J. G., PROC. NATL. ACAD. SCI. U.S.A, vol. 89, 1992, pages 10915 - 10919
ref_type: npl
severity: background
ref_id: - KNAPPIK ET AL., J. MOL. BIOL., vol. 296, 2000, pages 57 - 86
ref_type: npl
severity: background
ref_id: - CREIGHTON, PROTEINS, 1984
ref_type: npl
severity: background
ref_id: - MARKS ET AL., BIO/TECHNOLOGY, vol. 10, 1992, pages 779 - 783
ref_type: npl
severity: background
ref_id: - BARBAS ET AL., PROC NAT. ACAD. SCL USA, vol. 91, 1994, pages 3809 - 3813
ref_type: npl
severity: background
ref_id: - SCHIER ET AL., GENE, vol. 169, 1995, pages 147 - 155
ref_type: npl
severity: background
ref_id: - JACKSON ET AL., J. IMMUNOL., vol. 154, no. 7, 1995, pages 3310 - 9
ref_type: npl
severity: background
ref_id: - HAWKINS ET AL., J. MOL. BIOL., vol. 226, 1992, pages 889 - 896
ref_type: npl
severity: background
ref_id: - RIECHMANN, L. ET AL., NATURE, vol. 332, 1998, pages 323 - 327
ref_type: npl
severity: background
ref_id: - JONES, P. ET AL., NATURE, vol. 321, 1986, pages 522 - 525
ref_type: npl
severity: background
ref_id: - QUEEN, C. ET AL., PROC. NATL. ACAD. SCI. U.S.A., vol. 86, 1989, pages 10029 - 10033
ref_type: npl
severity: background
ref_id: - KABAT, E. A. ET AL.: "Sequences of Proteins of Immunological Interest", vol. 91, 1991, DEPARTMENT OF HEALTH AND HUMAN SERVICES, NIH, pages: 3242
ref_type: npl
severity: background
ref_id: - TOMLINSON, I. M. ET AL., J. FOL. BIOL., vol. 227, 1992, pages 776 - 798
ref_type: npl
severity: background
ref_id: - COX, J. P. L. ET AL., EUR. J IMMUNOL., vol. 24, 1994, pages 827 - 836
ref_type: npl
severity: background
ref_id: - LEFRANC, M.P. ET AL., NUCLEIC ACIDS RES., vol. 27, 1999, pages 209 - 212
ref_type: npl
severity: background
ref_id: - EGAN ET AL., MABS, vol. 9, no. 1, 2017, pages 68 - 84
ref_type: npl
severity: background
ref_id: - NIESEN ET AL., NATURE PROTOCOLS, vol. 2, no. 9, 2007, pages 2212 - 2221
ref_type: npl
severity: background
ref_id: - WONG; RALEIGH, PROTEIN SCIENCE, vol. 25, 2016, pages 1834 - 1840
ref_type: npl
severity: background
ref_id: - PLUCKTHUN: "The pharmacology of Monoclonal Antibodies", vol. 113, 1994, SPRINGER-VERLAG, pages: 269 - 315
ref_type: npl
severity: background
ref_id: - EGAN T. ET AL., MABS, vol. 9, 2017, pages 68 - 84
ref_type: npl
severity: background
ref_id: - MABS, vol. 9, no. 2, February 2017 (2017-02-01), pages 182 - 212
ref_type: npl
severity: background
ref_id: - HUDSON ET AL., NAT. MED., vol. 9, 2003, pages 129 - 134
ref_type: npl
severity: background
ref_id: - HOLLIGER ET AL., PROC. NATL. ACAD. SCI. U.S.A, vol. 90, 1993, pages 6444 - 6448
ref_type: npl
severity: background
ref_id: - FISCHER, N.; LEGER, O., PATHOBIOLOGY, vol. 74, 2007, pages 3 - 14
ref_type: npl
severity: background
ref_id: - HORNIG, N.; FARBER-SCHWARZ, A., METHODS MOL. BIOL., vol. 907, 2012, pages 713 - 727
ref_type: npl
severity: background
ref_id: - LABRIJN ET AL., PROC. NATL. ACAD. SCI. U.S.A, vol. 110, 2013, pages 5145 - 5150
ref_type: npl
severity: background
ref_id: - KRUIF ET AL., BIOTECHNOL. BIOENG., vol. 106, 2010, pages 741 - 750
ref_type: npl
severity: background
ref_id: - ZHU ET AL., CANCER LETT., vol. 86, 1994, pages 127 - 134
ref_type: npl
severity: background
ref_id: - SURESH ET AL., METHODS ENZYMOL., vol. 121, 1986, pages 210 - 228
ref_type: npl
severity: background
ref_id: - KARPOVSKY ET AL., J. EXP. MED., vol. 160, 1984, pages 1686
ref_type: npl
severity: background
ref_id: - LIU, M A ET AL., PROC. NATL. ACAD. SCI. U.S.A, vol. 82, 1985, pages 8648
ref_type: npl
severity: background
ref_id: - PAULUS, BEHRING INS. MITT., vol. 78, 1985, pages 118 - 132
ref_type: npl
severity: background
ref_id: - BRENNAN ET AL., SCIENCE, vol. 229, 1985, pages 81 - 83
ref_type: npl
severity: background
ref_id: - GLENNIE ET AL., J. IMMUNOL., vol. 139, 1987, pages 2367 - 2375
ref_type: npl
severity: background
ref_id: - BATZER ET AL., NUCLEIC ACID RES., vol. 19, 1991, pages 5081
ref_type: npl
severity: background
ref_id: - OHTSUKA ET AL., J. BIOL. CHEM., vol. 260, 1985, pages 2605 - 2608
ref_type: npl
severity: background
ref_id: - ROSSOLINI ET AL., MOL. CELL. PROBES, vol. 8, 1994, pages 91 - 98
ref_type: npl
severity: background
ref_id: - NARANG ET AL., METH. ENZYMOL, vol. 68, 1979, pages 90
ref_type: npl
severity: background
ref_id: - BROWN ET AL., METH. ENZYMOL., vol. 68, 1979, pages 109
ref_type: npl
severity: background
ref_id: - BEAUCAGE ET AL., TETRA. LETT., vol. 22, 1981, pages 1859
ref_type: npl
severity: background
ref_id: - "PCR Technology: Principles and Applications for DNA Amplification", 1992, FREEMAN PRESS
ref_type: npl
severity: background
ref_id: - "PCR Protocols: A Guide to Methods and Applications", 1990, ACADEMIC PRESS
ref_type: npl
severity: background
ref_id: - MATTILA ET AL., NUCLEIC ACIDS RES., vol. 19, 1991, pages 967
ref_type: npl
severity: background
ref_id: - ECKERT ET AL., PCR METHODS AND APPLICATIONS, vol. 1, 1991, pages 17
ref_type: npl
severity: background
ref_id: - HARRINGTON ET AL., NAT GENET., vol. 15, 1997, pages 345
ref_type: npl
severity: background
ref_id: - SMITH, ANNU. REV. MICROBIOL., vol. 49, 1995, pages 807
ref_type: npl
severity: background
ref_id: - ROSENFELD ET AL., CELL, vol. 68, 1992, pages 143
ref_type: npl
severity: background
ref_id: - SCHARF ET AL., RESULTS PROBL. CELL DIFFER., vol. 20, 1994, pages 125
ref_type: npl
severity: background
ref_id: - BITTNER ET AL., METH. ENZYMOL., vol. 153, 1987, pages 516
ref_type: npl
severity: background
ref_id: - WINNACKER: "FROM GENES TO CLONES", 1987, VCH PUBLISHERS
ref_type: npl
severity: background
ref_id: - QUEEN ET AL., IMMUNOL. REV., vol. 89, 1986, pages 49 - 68
ref_type: npl
severity: background
ref_id: - ELLIOT; O'HARE, CELL, vol. 88, 1997, pages 223
ref_type: npl
severity: background
ref_id: - REMINGTON: "The Science and Practice of Pharmacy", 2000, MACK PUBLISHING CO.
ref_type: npl
severity: background
ref_id: - "Sustained and Controlled Release Drug Delivery Systems", 1978, MARCEL DEKKER, INC.
ref_type: npl
severity: background
ref_id: - WU ET AL., TUMOUR BIOL., vol. 35, no. 6, 2014, pages 5347 - 56
ref_type: npl
severity: background
ref_id: - WU ET AL., PLOS ONE, vol. 7, no. 12, 2012
ref_type: npl
severity: background
ref_id: - ZHANG ET AL., ASIAN PAC J CANCER PREV, vol. 13, no. 8, 2012, pages 3955 - 60
ref_type: npl
severity: background
ref_id: - LIU ET AL., BIOCHEM BIOPHYS RES COMMUN, vol. 407, no. 2, 2011, pages 348 - 54
ref_type: npl
severity: background
ref_id: - CHEN ET AL., LUNG CANCER, vol. 69, no. 3, 2010, pages 348 - 54
ref_type: npl
severity: background
ref_id: - PUNT ET AL., ONCOIMMUNOLOGY, vol. 4, no. 2, 2015, pages e984547
ref_type: npl
severity: background
ref_id: - BORRAS ET AL., J. BIOL. CHEM., vol. 285, 2010, pages 9054 - 9066
ref_type: npl
severity: background
ref_id: - BORRAS ET AL., JBC., vol. 285, 2010, pages 9054 - 9066
ref_type: npl
severity: background
ref_id: - NIESEN ET AL., NAT PROTOC., vol. 2, 2007, pages 2212 - 21
ref_type: npl
severity: background
ref_id: - NIESEN, NATURE PROTOCOLS, vol. 2, no. 9, 2007
ref_type: npl
severity: background
ref_id: CN107488227A
ref_type: patent
severity: background
ref_id: US2019161544A1
ref_type: patent
severity: background
ref_id: WO2018011555A1
ref_type: patent
severity: background
ref_id: WO2018203289A1
ref_type: patent
severity: background
ref_id: WO2017221174A1
ref_type: patent
severity: background
ref_id: WO2014122613A1
ref_type: patent
severity: background
ref_id: WO2016138842A1
ref_type: patent
severity: background
ref_id: US2017327571A1
ref_type: patent
severity: background
ref_id: WO2016113557A1
ref_type: patent
severity: background
ref_id: WO2011053763A2
ref_type: patent
severity: background
ref_id: WO2007149032A1
ref_type: patent
severity: background
ref_id: WO2008021156A2
ref_type: patent
severity: background
ref_id: WO2014001368A1
ref_type: patent
severity: background
ref_id: WO2015070697A1
ref_type: patent
severity: background
ref_id: WO2015137843A1
ref_type: patent
severity: background
ref_id: WO2016048188A1
ref_type: patent
severity: background
ref_id: - "Therapy for Severe Psoriasis", 1 January 2016, ELSEVIER, ISBN: 978-0-323-44797-3, article SHIVANI P. REDDY ET AL: "Ixekizumab", pages: 153 - 162, XP055604697, DOI: 10.1016/B978-0-323-44797-3.00013-X
ref_type: npl
severity: background
ref_id: WO2007149032
ref_type: patent
severity: obviousness
ref_id: WO2008021156
ref_type: patent
severity: obviousness
ref_id: WO2011053763
ref_type: patent
severity: obviousness
ref_id: WO2014001368
ref_type: patent
severity: obviousness
ref_id: WO2014122613
ref_type: patent
severity: obviousness
ref_id: WO2015070697
ref_type: patent
severity: obviousness
ref_id: WO2015137843
ref_type: patent
severity: obviousness
ref_id: WO2016048188
ref_type: patent
severity: obviousness
ref_id: WO2016113557
ref_type: patent
severity: obviousness
ref_id: WO2016138842
ref_type: patent
severity: obviousness
ref_id: US2017327571
ref_type: patent
severity: obviousness
ref_id: CN107488227
ref_type: patent
severity: obviousness
ref_id: WO2017221174
ref_type: patent
severity: obviousness
ref_id: WO2018011555
ref_type: patent
severity: obviousness
ref_id: WO2018203289
ref_type: patent
severity: obviousness
ref_id: US2019161544
ref_type: patent
severity: novelty_destroying
ref_id: - Shivani P. Reddy ET AL, "Ixekizumab", Therapy for Severe Psoriasis, Elsevier, (20160101), pages 153 - 162, doi:10.1016/B978-0-323-44797-3.00013-X, ISBN 978-0-323-44797-3, XP055604697 [I] 1-15 * abstract * [Y] 1-15
ref_type: npl
severity: obviousness
Final disposition: pending (2020-08-05)